Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free AURA Stock Alerts

Aura Biosciences (AURA) Competitors

Aura Biosciences logo
$6.10 -0.24 (-3.79%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$6.11 +0.01 (+0.16%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AURA vs. RXRX, CLDX, IRON, NRIX, and SLS

Should you buy Aura Biosciences stock or one of its competitors? Aura Biosciences's main competitors and comparable companies include Recursion Pharmaceuticals (RXRX), Celldex Therapeutics (CLDX), Disc Medicine (IRON), Nurix Therapeutics (NRIX), and SELLAS Life Sciences Group (SLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aura Biosciences compare to Recursion Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Aura Biosciences has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -945.94%. Recursion Pharmaceuticals' return on equity of -50.41% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals-945.94% -50.41% -38.25%
Aura Biosciences N/A -73.18%-62.00%

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aura Biosciences has lower revenue, but higher earnings than Recursion Pharmaceuticals. Aura Biosciences is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$74.68M24.80-$644.76M-$1.04N/A
Aura BiosciencesN/AN/A-$106.19M-$1.75N/A

In the previous week, Recursion Pharmaceuticals had 12 more articles in the media than Aura Biosciences. MarketBeat recorded 12 mentions for Recursion Pharmaceuticals and 0 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.82 beat Recursion Pharmaceuticals' score of 0.58 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Recursion Pharmaceuticals Positive
Aura Biosciences Very Positive

Recursion Pharmaceuticals currently has a consensus price target of $8.18, indicating a potential upside of 136.42%. Aura Biosciences has a consensus price target of $17.50, indicating a potential upside of 186.89%. Given Aura Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Recursion Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Recursion Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

Summary

Recursion Pharmaceuticals beats Aura Biosciences on 7 of the 13 factors compared between the two stocks.

How does Aura Biosciences compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Celldex Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Celldex Therapeutics' return on equity of -52.35% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Celldex TherapeuticsN/A -52.35% -47.61%
Aura Biosciences N/A -73.18%-62.00%

In the previous week, Celldex Therapeutics had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 2 mentions for Celldex Therapeutics and 0 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.82 beat Celldex Therapeutics' score of 0.70 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Celldex Therapeutics Positive
Aura Biosciences Very Positive

96.8% of Aura Biosciences shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 1.9% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Celldex Therapeutics currently has a consensus price target of $61.92, suggesting a potential upside of 124.93%. Aura Biosciences has a consensus price target of $17.50, suggesting a potential upside of 186.89%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Aura Biosciences has lower revenue, but higher earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celldex Therapeutics$1.54M1,403.85-$258.76M-$4.35N/A
Aura BiosciencesN/AN/A-$106.19M-$1.75N/A

Summary

Celldex Therapeutics beats Aura Biosciences on 9 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Disc Medicine has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Disc Medicine's return on equity of -37.17% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Disc MedicineN/A -37.17% -33.65%
Aura Biosciences N/A -73.18%-62.00%

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Disc Medicine currently has a consensus target price of $110.18, indicating a potential upside of 93.85%. Aura Biosciences has a consensus target price of $17.50, indicating a potential upside of 186.89%. Given Aura Biosciences' higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Disc Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Disc Medicine
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Disc Medicine had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Disc Medicine and 0 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.82 beat Disc Medicine's score of 0.97 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Disc Medicine Positive
Aura Biosciences Very Positive

Disc Medicine is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Disc MedicineN/AN/A-$212.18M-$6.58N/A
Aura BiosciencesN/AN/A-$106.19M-$1.75N/A

Summary

Disc Medicine beats Aura Biosciences on 7 of the 12 factors compared between the two stocks.

How does Aura Biosciences compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

Nurix Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

Aura Biosciences has lower revenue, but higher earnings than Nurix Therapeutics. Aura Biosciences is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix Therapeutics$83.98M31.77-$264.46M$2.3110.57
Aura BiosciencesN/AN/A-$106.19M-$1.75N/A

In the previous week, Nurix Therapeutics had 25 more articles in the media than Aura Biosciences. MarketBeat recorded 25 mentions for Nurix Therapeutics and 0 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.82 beat Nurix Therapeutics' score of 0.46 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Nurix Therapeutics Neutral
Aura Biosciences Very Positive

Nurix Therapeutics presently has a consensus price target of $34.79, indicating a potential upside of 42.45%. Aura Biosciences has a consensus price target of $17.50, indicating a potential upside of 186.89%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Nurix Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nurix Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

96.8% of Aura Biosciences shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by insiders. Comparatively, 1.9% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Nurix Therapeutics has a net margin of 42.01% compared to Aura Biosciences' net margin of 0.00%. Nurix Therapeutics' return on equity of 49.34% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Nurix Therapeutics42.01% 49.34% 38.61%
Aura Biosciences N/A -73.18%-62.00%

Summary

Nurix Therapeutics beats Aura Biosciences on 10 of the 14 factors compared between the two stocks.

How does Aura Biosciences compare to SELLAS Life Sciences Group?

Aura Biosciences (NASDAQ:AURA) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Aura Biosciences currently has a consensus price target of $17.50, suggesting a potential upside of 186.89%. SELLAS Life Sciences Group has a consensus price target of $10.00, suggesting a potential upside of 0.20%. Given Aura Biosciences' higher probable upside, equities research analysts plainly believe Aura Biosciences is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aura Biosciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 1 mentions for SELLAS Life Sciences Group and 0 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.82 beat SELLAS Life Sciences Group's score of 0.61 indicating that Aura Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Aura Biosciences Very Positive
SELLAS Life Sciences Group Positive

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by company insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aura Biosciences has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.56, meaning that its share price is 156% more volatile than the broader market.

SELLAS Life Sciences Group's return on equity of -35.91% beat Aura Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aura BiosciencesN/A -73.18% -62.00%
SELLAS Life Sciences Group N/A -35.91%-33.34%

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aura BiosciencesN/AN/A-$106.19M-$1.75N/A
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.21N/A

Summary

SELLAS Life Sciences Group beats Aura Biosciences on 6 of the 10 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AURA vs. The Competition

Export
MetricAura BiosciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$657.49M$3.97B$7.44B$12.94B
Dividend YieldN/A3.64%2.50%27.63%
P/E Ratio-3.499.98200.1619.16
Price / SalesN/A1,175.02569.1876.54
Price / CashN/A122.1076.5451.88
Price / Book2.8215.9410.295.85
Net Income-$106.19M-$22.69M$3.50B$380.67M
7 Day Performance-6.73%-8.66%-5.38%-5.00%
1 Month Performance-7.44%-15.39%-9.56%-7.94%
1 Year Performance7.58%1.51%0.85%-5.63%

Aura Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AURA
Aura Biosciences
2.2926 of 5 stars		$6.10
-3.8%		$17.50
+186.9%		-1.5%$657.49MN/AN/A113
RXRX
Recursion Pharmaceuticals
2.4727 of 5 stars		$4.63
-3.1%		$8.06
+74.1%		-45.6%$2.48B$53.94MN/A600
CLDX
Celldex Therapeutics
2.5858 of 5 stars		$31.00
-4.9%		$61.92
+99.8%		+3.7%$2.43B$158KN/A198
IRON
Disc Medicine
2.427 of 5 stars		$61.65
-2.7%		$110.18
+78.7%		-23.6%$2.37BN/AN/A165
NRIX
Nurix Therapeutics
3.5387 of 5 stars		$22.60
-1.2%		$34.21
+51.4%		+143.5%$2.35B$36.77MN/A357

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AURA) was last updated on 10/17/2026 by MarketBeat.com Staff.
From Our Partners
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel